DexCom Inc
NASDAQ: DXCM · HEALTHCARE · MEDICAL DEVICES
Updated 2026-06-05
DexCom Inc (DXCM) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-43.73M | $-33.21M | $-37.45M | $-39.39M | $-42.68M | $-30.13M | $-33.10M | $2.40M | $23.60M | $49.00M | $56.20M | $92.00M | $123.20M | $314.50M | $475.60M | $442.50M | $669.50M | $748.50M | $989.50M | $1.44B |
| Capital expenditures | $3.35M | $3.44M | $2.49M | $2.99M | $6.86M | $8.01M | $9.50M | $7.90M | $16.20M | $33.30M | $55.70M | $66.00M | $67.10M | $180.00M | $199.00M | $389.20M | $364.80M | $236.60M | $358.80M | $363.50M |
| Depreciation | $2.70M | $3.33M | $3.58M | $2.37M | $2.44M | $3.76M | $6.60M | $7.00M | $8.40M | $10.80M | $15.00M | $16.10M | $29.10M | $48.70M | $67.10M | $102.00M | $155.90M | $186.00M | $217.70M | $251.80M |
| Stock-based comp | $5.85B | $6.12M | $7.68M | $8.37M | $9.44M | $13.51M | $18.40M | $24.60M | $50.00M | $82.70M | $110.80M | $106.20M | $101.90M | $102.70M | $119.40M | $113.40M | $126.50M | $150.80M | $170.40M | $159.60M |
| Free cash flow | $-47.09M | $-36.65M | $-39.94M | $-42.38M | $-49.54M | $-38.13M | $-42.60M | $-5.50M | $7.40M | $15.70M | $500000.00 | $26.00M | $56.10M | $134.50M | $276.60M | $53.30M | $304.70M | $511.90M | $630.70M | $1.08B |
| Investing cash flow | $-26.56M | $-8.44M | $24.32M | $-14.10M | $-25.61M | $-46.37M | $28.40M | $20.90M | $-16.80M | $-51.50M | $-55.90M | $-144.40M | $-139.80M | $-1.02B | $-1.02B | $-216.10M | $-521.50M | $-507.20M | $-207.50M | $536.00M |
| Financing cash flow | $51.21M | $46.60M | $2.71M | $44.38M | $69.65M | $74.18M | $10.20M | $11.80M | $21.80M | $16.80M | $8.10M | $399.10M | $710.40M | $10.70M | $912.10M | $10.40M | $-552.50M | $-318.60M | $-734.80M | $-1.69B |
| Dividends paid | — | — | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — | $1.23B | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | $-2.34M | $5.50M | $35.10M | $28.60M | $14.30M | $8.40M | $347.00M | $693.80M | $-690.00M | $369.70M | $236.80M | $-404.50M | — | — | — |
Frequently asked questions
What is DexCom Inc's revenue?
DexCom Inc's trailing twelve-month revenue is $4.82B, and consensus projects about $8.52B by 2030. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is DXCM?
In its most recent fiscal year, DXCM ran a gross margin of 60.01%, an operating margin of 19.56%, and a net margin of 17.94%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does DXCM generate?
DXCM produced $1.08B in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is DXCM's balance sheet healthy?
DXCM holds $917.70M in cash and equivalents against $1.24B in long-term debt, on $2.75B of shareholder equity. That debt is best read against the cash flow the business throws off each year.